Compare Genuine Parts Company (GPC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Natera Inc. Common Stock — how do they compare? Genuine Parts Company trades at $131.49 (market cap $18.02B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.2× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.25% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Natera Inc. Common Stock for 0 Days on average.
| GPC | NTRA | |
|---|---|---|
Market Cap | $18.02B | $57.03B |
Volume | 744,000 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $425.64 |
52-Week Low | $92.47 | $179.42 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.11B | $56.18B |
Dividend Yield | 3.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $131.63, up 1.55% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss, while net income margin remains thin at 0.13%. The company is progressing with its planned separation into automotive and industrial businesses by Q1 2027, a key strategic move highlighted in recent news.
The outlook is cautiously optimistic, supported by the corporate split catalyst and steady revenue growth, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though valuation metrics like a high P/E of 522.84 warrant attention for potential investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
